Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ding Ren

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Medchemcomm|August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulatorsDavid Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|August 20, 2004
Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activityPing Chen, Arthur M Doweyko, Derek Norris, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Journal of Medicinal Chemistry|December 13, 2007
Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitorsJohn Hynes, Alaric J Dyckman, Shuqun Lin, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Journal of Medicinal Chemistry|September 1, 2010
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesChunjian Liu, James Lin, Stephen T Wrobleski, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Medchemcomm|August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulatorsDavid Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
Pageof 9